If you have a scar that doesn’t seem to be fading, or even appears to be growing in size, it is important to determine whether that scar is a keloid or not. There are two types of raised scars: keloid and hypertrophic. While both hypertrophic scars and keloid scars themselves are benign, the uncontrolled growth […]
Blog
Sensus Healthcare Receives the BioFlorida Company of the Year Award
BOCA RATON, Fla., Dec. 13, 2016 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers (NMSC) and other skin conditions such as keloids with superficial radiation therapy (SRT), announced today that it has been named the winner of the BioFlorida Company of the Year Award at […]
Regain Your Confidence with Non-Surgical Treatment for Your Keloid Scar
If you are one of the nearly 18 million people affected by ugly and sometimes painful keloid scars, you know first-hand just how embarrassing they can be. We have good news for you. You can regain your confidence with SRT therapy, a non-surgical option for treating keloid scars after surgical removal. What Causes a Keloid […]
Sensus Healthcare to Participate in Two Upcoming Investor Conferences on November 30th and December 1st
— Evercore ISI MedTools Investor Conference in Boston, MA — Drexel Hamilton’s Emerging Growth Conference in New York, NY BOCA RATON, Fla., Nov. 16, 2016 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy (SRT), […]
Sensus Healthcare Reports Third Quarter 2016 Results
– Q3 revenues increased 58% year-over-year to $3.33 million – Worldwide installed base increased to 256 units BOCA RATON, Fla., Nov. 3, 2016 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy (SRT), today reported […]
Patients Benefit from Non-Surgical SRT
If you’ve been diagnosed with non-melanoma skin cancer, such as basal cell carcinoma or squamous cell carcinoma, you now have a new, non-surgical option for treatment. Superficial Radio Therapy (SRT) with the SRT-100™ delivers a precise, calibrated dose of SRT that only goes skin deep. This low-dose of Superficial Radio Therapy safely destroys non-melanoma skin […]
Physicians Prefer SRT Therapy for Treatment of Non-Melanoma Skin Cancer and Keloid Scars
Eighteen million people are affected by unsightly and sometimes painful keloid scars, and many of them go through life believing treatment for this embarrassing condition is next to impossible, if possible at all. You can help restore your patient’s confidence and self-esteem by offering keloid treatment with Superficial Radio Therapy (SRT therapy) following surgical removal. […]
Sensus Healthcare to Announce Third Quarter 2016 Results on November 3, 2016
BOCA RATON, Fla., Oct. 20, 2016 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy, today announced that it will report its third quarter 2016 financial results on Thursday, November 3, 2016 after the market […]
New study highlights need for routine skin cancer screening for all transplant patients
Drexel University College of Medicine study suggests all organ transplant recipients should receive total-body screenings for skin cancer
Sensus Healthcare to Participate in Important Dermatological and Institutional Investor Conferences from October 20th to October 23rd
–2016 Fall Clinical Dermatology Conference in Las Vegas, NV –Dawson James 2016 Small Cap Growth Stock Conference in Jupiter, FL BOCA RATON, Fla., Oct. 6, 2016 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy […]
SRT-100™: A Painless, Non-Invasive, Non-Melanoma Skin Cancer Treatment Right in Your Office
Whether you are a radiation oncologist or a dermatologist, you can enhance your patient care with the SRT-100™ non-melanoma skin cancer treatment.
SRT-100™: A Non-Melanoma Skin Cancer Treatment Your Body Can Handle, but Cancer Cannot
Skin cancer is the fastest growing cancer in the world. Experts predict the number of people diagnosed with non-melanoma skin cancer will grow to nearly six million by the year 2020. With the epidemic of basal and squamous cell skin cancer diagnosis follows the common and less than ideal solution of surgical non-melanoma skin cancer […]
Sensus Healthcare, Inc. Receives the Frost & Sullivan 2016 Global Non-melanoma Skin Cancer Therapy Technology Leadership Award
– Sensus Credited with Advancing Superficial Radio Therapy as Viable Treatment Option for NMSC – BOCA RATON, Fla., Sept. 7, 2016 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers (NMSC) and other skin conditions such as keloids with superficial radiation therapy (SRT), announced today it […]
Sensus Healthcare to Sponsor First International Keloid Symposium on September 8 and 9 in New York
BOCA RATON, Fla., Aug. 31, 2016 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy (SRT), today announced that the Company will sponsor the First International Keloid Symposium to be held at The Rockefeller University […]
Ask Your Doctor About the SRT-100™ to Treat Your Basal Cell Carcinoma
Have you been diagnosed with skin cancer? You are not alone. Skin cancer is one of the most commonly occurring forms of cancer, with more than one in every three new cancers diagnosed as skin cancer. Basal cell carcinoma is one type of skin cancer and occurs more frequently than any other form of skin […]
Treat Your Patients’ Basal Cell Carcinoma with the Revolutionary SRT-100™
Any dermatologist knows just how devastating a skin cancer diagnosis can be to his or her patients. Skin cancer is diagnosed nearly three times as often as any other form of cancer, with the most common of all skin cancers being basal cell carcinoma. While patients facing basal cell carcinoma have multiple choices available for […]
Hear What Patients and Physicians Have to Say About the SRT-100™ for Keloid Treatment
Patients and physicians both are talking about revolutionary keloid treatment offered by the SRT-100™. Hear what they have to say. :
Sensus Healthcare Reports Second Quarter 2016 Results
– Q2 revenues increased 49% year-over-year to $3.6 million – Worldwide installed base increased to 247 units -Successfully completed IPO on June 2nd; cash of $15.8 million, with no debt, at June 30, 2016 BOCA RATON, Fla., Aug. 4, 2016 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of […]
Mike Masterson: Arkansas Approves Zapping Cancers
By Mike Masterson Posted: August 2, 2016 at 5:45 a.m. Editor’s note: The original version of the column was published March 9, 2014. There the thing still was, frowning from the mirror. That crusty red spot on the very tip of my nose wasn’t going away despite weeks of salves. It appeared to be steadily […]
Sensus Healthcare to Announce Second Quarter 2016 Results on August 4, 2016
BOCA RATON, Fla., Aug. 2, 2016 — Sensus Healthcare, Inc. (NASDAQ: SRTS; SRTSW), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy, today provided a reminder that it will report its second quarter 2016 financial results on Thursday, August 4, 2016 […]